Oncology Assessment for Biosimilar In-licensing

The head of marketing for a biopharma company’s biosimilars business unit was struggling to size two oncology in-licensing opportunities in the U.S. and Europe. Looking for an informed assessment—and a broader picture of biosimilar developments in the oncology market—she turned to Business Talent Group.

Our consultant had a PhD in Chemistry and an MBA from London Business School; he’d worked as a Project Leader in BCG’s healthcare practice and led Drug Discovery and Early Clinical Development at Sanofi. First, he outlined key oncology customer segments, reimbursement and formulary stakeholders, and market dynamics and drivers for the two target molecules. Then he used the company’s internal financial valuation model to inform a go/no-go decision.

Send this to a friend